Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Financial Statements and Exhibits

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

Story continues below

(d) Exhibits.


AGIOS PHARMACEUTICALS INC Exhibit
EX-99.1 2 d554924dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   FDA Grants Approval of TIBSOVO®,…
To view the full exhibit click here

About Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.

An ad to help with our costs